Home › Companies › CRINETICS PHARMACEUTICALS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and CRINETICS PHARMACEUTICALS INC.’s Form 8-K, filed June 10, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 7, 2024: 4 items on CRINETICS PHARMACEUTICALS INC.’s Form 8-K, filed June 10, 2024: 2 approved · 2 passed (calculated).
Significant dissent: 2 directors (23.5%, 22.7% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore CRINETICS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are CRINETICS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Camille Bedrosian, M.D. | 50,829,173 | -- | -- | 14,947,321 | 2,328,910 | 77% | Passed (calculated) | — |
| Elect Director: Wendell Wierenga, Ph.D. | 50,300,772 | -- | -- | 15,475,722 | 2,328,910 | 76% | Passed (calculated) | — |
| 2. Ratification of Selection of Independent Registered Accounting Firm | 67,973,983 | 115,422 | 15,999 | -- | 0 | 99.8% | Approved | — |
| 3. Approval, on an advisory basis, of the compensation of the Company's named executive officers | 64,052,127 | 1,745,589 | 6,019 | -- | 2,301,669 | 97% | Approved | — |
Source: CRINETICS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 10, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
246 asset managers disclosed a vote on at least one CRINETICS PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
77% Majority: yes · of votes cast
Description as filed by funds: To elect two directors to serve as Class III directors for a three-year term to expire at the 2027 annual meeting of stockholders: Camille Bedrosian, M.D.
CRINETICS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Camille Bedrosian, M.D.”): 50,829,173 for, 14,947,321 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 86 asset managers below reported 24,727,122 for, 128 against, 4,324,565 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 5,530,165 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,733,729 | 0 | 0 | 0 | For |
| Vanguard | 3,467,622 | 0 | 0 | 0 | For |
| BlackRock | 2,356,253 | 0 | 0 | 0 | For |
| Prudential/PGIM | 1,693,762 | 0 | 0 | 124,143 | Mixed |
| State Street | 1,757,917 | 0 | 0 | 25,749 | For |
| MUTUAL FUND SERIES TRUST | 1,059,633 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 24,659 | 0 | 0 | 810,729 | Withhold |
| JANUS INVESTMENT FUND | 574,422 | 0 | 0 | 144,507 | Mixed |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 614,365 | Withhold |
| Lord Abbett | 0 | 0 | 0 | 585,764 | Withhold |
| Charles Schwab | 481,426 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 450,780 | Withhold |
| TIAA | 440,232 | 0 | 0 | 0 | For |
| Hartford | 403,084 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 2,238 | 0 | 0 | 269,041 | Withhold |
| JPMorgan | 248,704 | 0 | 0 | 0 | For |
| John Hancock | 217,964 | 0 | 0 | 24,073 | Mixed |
| Equitable | 192,375 | 0 | 0 | 31,268 | Mixed |
| Victory Capital | 1,240 | 0 | 0 | 208,597 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 173,991 | Withhold |
| First Trust | 0 | 0 | 0 | 168,294 | Withhold |
| FRANKLIN STRATEGIC SERIES | 130,922 | 0 | 0 | 0 | For |
| Invesco | 129,569 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 122,957 | 0 | 0 | 0 | For |
Showing the 25 largest of 86 asset managers. All 86 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
76% Majority: yes · of votes cast
Description as filed by funds: To elect two directors to serve as Class III directors for a three-year term to expire at the 2027 annual meeting of stockholders: Wendell Wierenga, Ph.D.
CRINETICS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Wendell Wierenga, Ph.D.”): 50,300,772 for, 15,475,722 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 86 asset managers below reported 24,462,565 for, 128 against, 4,589,122 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 5,530,165 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,733,729 | 0 | 0 | 0 | For |
| Vanguard | 3,467,622 | 0 | 0 | 0 | For |
| BlackRock | 2,356,253 | 0 | 0 | 0 | For |
| Prudential/PGIM | 1,693,762 | 0 | 0 | 124,143 | Mixed |
| State Street | 1,757,917 | 0 | 0 | 25,749 | For |
| MUTUAL FUND SERIES TRUST | 1,059,633 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 24,659 | 0 | 0 | 810,729 | Withhold |
| JANUS INVESTMENT FUND | 574,422 | 0 | 0 | 144,507 | Mixed |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 614,365 | Withhold |
| Lord Abbett | 0 | 0 | 0 | 585,764 | Withhold |
| Charles Schwab | 481,426 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 450,780 | Withhold |
| TIAA | 440,232 | 0 | 0 | 0 | For |
| Hartford | 403,084 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 2,238 | 0 | 0 | 269,041 | Withhold |
| JPMorgan | 248,704 | 0 | 0 | 0 | For |
| John Hancock | 217,964 | 0 | 0 | 24,073 | Mixed |
| Equitable | 126,105 | 0 | 0 | 97,538 | Mixed |
| Victory Capital | 1,240 | 0 | 0 | 208,597 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 173,991 | Withhold |
| First Trust | 0 | 0 | 0 | 168,294 | Withhold |
| FRANKLIN STRATEGIC SERIES | 130,922 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 129,569 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 122,957 | 0 | 0 | 0 | For |
Showing the 25 largest of 86 asset managers. All 86 are in the interactive database (link above).
Combines 16 wordings of this item as funds reported it.
97% Approved · of votes cast
Prior year: 97.4% for (June 16, 2023 meeting) ▼ 0.1 pts
Description as filed by funds: To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; and
CRINETICS PHARMACEUTICALS INC.’s own tally for this item (“3. Approval, on an advisory basis, of the compensation of the Company's named executive officers”): 64,052,127 for, 1,745,589 against — passed, per its Form 8-K filed June 10, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal Three - Approval, on an advisory basis, of the compensation of the Company's named executive officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 5,530,165 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,733,729 | 0 | 0 | 0 | For |
| Vanguard | 3,467,622 | 0 | 0 | 0 | For |
| BlackRock | 2,356,253 | 0 | 0 | 0 | For |
| Prudential/PGIM | 1,796,489 | 21,416 | 0 | 0 | For |
| State Street | 1,776,389 | 7,277 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,059,633 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 811,987 | 23,401 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 718,929 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 614,365 | 0 | 0 | 0 | For |
| Lord Abbett | 585,764 | 0 | 0 | 0 | For |
| Charles Schwab | 481,426 | 0 | 0 | 0 | For |
| Dimensional | 450,780 | 0 | 0 | 0 | For |
| TIAA | 440,232 | 0 | 0 | 0 | For |
| Hartford | 403,084 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 271,279 | 0 | 0 | 0 | For |
| JPMorgan | 248,704 | 0 | 0 | 0 | For |
| John Hancock | 242,037 | 0 | 0 | 0 | For |
| Equitable | 223,643 | 0 | 0 | 0 | For |
| Victory Capital | 209,837 | 0 | 0 | 0 | For |
| Goldman Sachs | 173,991 | 0 | 0 | 0 | For |
| First Trust | 168,294 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 130,922 | 0 | 0 | 0 | For |
| Invesco | 0 | 129,569 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 122,957 | 0 | 0 | 0 | For |
Fund voting reports, all 85 managers: 28,800,903 for, 250,784 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 6,419,646 | 0 | 0 | 0 | For |
| Fidelity | 4,458,183 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 3,820,421 | 0 | 0 | 0 | For |
| State Street | 3,007,845 | 27,291 | 0 | 0 | For |
| Point72 | 2,789,934 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 2,596,968 | 5,054 | 0 | 0 | For |
| Wellington | 2,192,157 | 0 | 0 | 0 | For |
| Paradigm Biocapital Advisors LP | 2,140,458 | 0 | 0 | 0 | For |
| EcoR1 Capital, LLC | 2,012,517 | 0 | 0 | 0 | For |
| BlackRock | 1,971,119 | 12,267 | 0 | 0 | For |
| First Light Asset Management, LLC | 1,631,938 | 0 | 0 | 0 | For |
| Janus Henderson | 1,610,539 | 2,972 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,400,846 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 1,280,800 | 0 | 0 | 0 | For |
| Cormorant Asset Management, LP | 1,217,632 | 0 | 0 | 0 | For |
| Novo Holdings A/S | 1,098,600 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 1,000,012 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 858,828 | 0 | 0 | 0 | For |
| LORD, ABBETT & CO. LLC | 790,403 | 0 | 0 | 0 | For |
| Laurion Capital Management LP | 598,167 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 594,037 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 542,708 | 0 | 0 | Against |
| JPMorgan | 516,773 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 516,414 | 0 | 0 | 0 | For |
| Nuveen | 493,947 | 0 | 0 | 0 | For |
Institutional-manager reports, all 188 managers: 51,786,031 for, 1,492,954 against, 1,260 abstained, 800 not voted, 11 unknown. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Prior year: 100.0% for (June 16, 2023 meeting) ▼ 0.2 pts
Description as filed by funds: To consider and vote upon the ratification of the selection of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
CRINETICS PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of Selection of Independent Registered Accounting Firm”): 67,973,983 for, 115,422 against — passed, per its Form 8-K filed June 10, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal Two - Ratification of Selection of Independent Registered Accounting Firm The Company's stockholders ratified the selection of BDO USA, P.C. as the Company's independent registered accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 86 asset managers below reported 29,048,580 for, 3,235 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 5,530,165 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,733,729 | 0 | 0 | 0 | For |
| Vanguard | 3,467,622 | 0 | 0 | 0 | For |
| BlackRock | 2,356,253 | 0 | 0 | 0 | For |
| Prudential/PGIM | 1,817,905 | 0 | 0 | 0 | For |
| State Street | 1,780,625 | 3,041 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,059,633 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 835,388 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 718,929 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 614,365 | 0 | 0 | 0 | For |
| Lord Abbett | 585,764 | 0 | 0 | 0 | For |
| Charles Schwab | 481,426 | 0 | 0 | 0 | For |
| Dimensional | 450,780 | 0 | 0 | 0 | For |
| TIAA | 440,232 | 0 | 0 | 0 | For |
| Hartford | 403,084 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 271,279 | 0 | 0 | 0 | For |
| JPMorgan | 248,704 | 0 | 0 | 0 | For |
| John Hancock | 242,037 | 0 | 0 | 0 | For |
| Equitable | 223,643 | 0 | 0 | 0 | For |
| Victory Capital | 209,837 | 0 | 0 | 0 | For |
| Goldman Sachs | 173,991 | 0 | 0 | 0 | For |
| First Trust | 168,294 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 130,922 | 0 | 0 | 0 | For |
| Invesco | 129,569 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 122,957 | 0 | 0 | 0 | For |
Showing the 25 largest of 86 asset managers. All 86 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 78,539,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 7.04% |
| 2 | T. Rowe Price | 6.03% |
| 3 | Vanguard | 4.42% |
| 4 | BlackRock | 3.00% |
| 5 | Prudential/PGIM | 2.31% |
| 6 | State Street | 2.27% |
| 7 | MUTUAL FUND SERIES TRUST | 1.35% |
| 8 | Bridge Builder Trust | 1.06% |
| 9 | JANUS INVESTMENT FUND | 0.92% |
| 10 | DRIEHAUS MUTUAL FUNDS | 0.78% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | T. Rowe Price | 8.17% |
| 2 | Fidelity | 5.68% |
| 3 | DRIEHAUS CAPITAL MANAGEMENT LLC | 4.86% |
| 4 | State Street | 3.86% |
| 5 | Point72 | 3.55% |
| 6 | JENNISON ASSOCIATES LLC | 3.31% |
| 7 | Wellington | 2.79% |
| 8 | Paradigm Biocapital Advisors LP | 2.73% |
| 9 | EcoR1 Capital, LLC | 2.56% |
| 10 | BlackRock | 2.53% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| FMR (Fidelity) | 14,187,498 | 18.06% | Form 13F, quarter ended March 31, 2024 |
| Vanguard Group | 9,170,129 | 11.68% | Form 13F, quarter ended March 31, 2024 |
| BlackRock | 7,586,597 | 9.66% | Form 13F, quarter ended March 31, 2024 |
| Point72 | 4,949,486 | 6.30% | Form 13F, quarter ended March 31, 2024 |
| T. Rowe Price | 3,823,218 | 4.87% | Form 13F, quarter ended March 31, 2024 |
| State Street | 3,255,253 | 4.14% | Form 13F, quarter ended March 31, 2024 |
| Wellington Management | 2,971,582 | 3.78% | Form 13F, quarter ended March 31, 2024 |
| Perceptive Advisors LLC | 1,488,703 | 1.90% | Schedule 13D, filed March 1, 2024 |
| Geode Capital | 1,401,403 | 1.78% | Form 13F, quarter ended March 31, 2024 |
| JPMorgan Chase | 1,258,722 | 1.60% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 78,539,000 shares outstanding, as reported by CRINETICS PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At CRINETICS PHARMACEUTICALS INC.'s shareholder meeting held June 7, 2024, in the 2023-2024 proxy season, 246 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,495 separate fund positions. On the most widely held item on that ballot — To consider and vote upon, on an advisory basis, the compensation of the Company's named… — CRINETICS PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: CRINETICS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CRINETICS PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
CRINETICS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “CRINETICS PHARMACEUTICALS INC. 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/crinetics-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.